Reversal of Mycobacterium tuberculosis phenotypic drug resistance by 2-aminoimidazole-based small molecules

Pathogens and Disease

Volumn 70, Issue 3, 2014, Pages 370-378

  Ackart, David F ^a   Lindsey, Erick A ^b   Podell, Brendan K ^a   Melander, Roberta J ^b   Basaraba, Randall J ^a   Melander, Christian ^b  

^a Department of Environmental and Radiological Health Sciences   (United States)

^b NORTH CAROLINA STATE UNIVERSITY   (United States)

Author keywords

2 aminoimidazole; Biofilm; Drug resistant; Drug tolerant; Isoniazid; Tuberculosis

Indexed keywords

2 AMINOBENZIMIDAZOLE DERIVATIVE; 2 AMINOPYRIMIDINE DERIVATIVE; IMIDAZOLE DERIVATIVE; ISONIAZID; UNCLASSIFIED DRUG; 2-AMINOIMIDAZOLE; TUBERCULOSTATIC AGENT;

ANTIBIOTIC SENSITIVITY; ARTICLE; BIOFILM; DRUG SCREENING; DRUG STRUCTURE; DRUG TOLERANCE; EXTRACELLULAR MATRIX; IN VITRO STUDY; LEUKOCYTE; MICROBIAL COMMUNITY; MYCOBACTERIUM SMEGMATIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHENOTYPIC VARIATION; PRIORITY JOURNAL; ANTIBIOTIC RESISTANCE; CHEMISTRY; DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING; HUMAN; MICROBIAL SENSITIVITY TEST; PHENOTYPE; PHYSIOLOGY;

ANTITUBERCULAR AGENTS; BIOFILMS; DRUG RESISTANCE, BACTERIAL; HUMANS; IMIDAZOLES; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM SMEGMATIS; MYCOBACTERIUM TUBERCULOSIS; PHENOTYPE;

EID: 84920131926     PISSN: None     EISSN: 2049632X     Source Type: Journal    
DOI: 10.1111/2049-632X.12143     Document Type: Article

References (37)

1. Ahmad S & Mokaddas E. (2013) Current status and future trends in the diagnosis and treatment of drug-susceptible and multidrug- resistant tuberculosis. J Infect Public Health.
2. Ahmad Z, Klinkenberg LG, Pinn ML et al. (2009) Biphasic kill curve of isoniazid reveals the presence of drug-tolerant, not drug-resistant, Mycobacterium tuberculosis in the guinea pig. J Infect Dis 200: 1136-1143.
3. Andreu N, Fletcher T, Krishnan N, Wiles S & Robertson BD (2012) Rapid measurement of antituberculosis drug activity in vitro and in macrophages using bioluminescence. J Antimicrob Chemother 67: 404-414.
4. Ballard TE, Richards JJ, Wolfe AL & Melander C (2008) Synthesis and antibiofilm activity of a second-generation reverse-amide oroidin library: a structure-activity relationship study. Chemistry 14: 10745-10761.
5. Barclay WR, Ebert RH, Manthei RW & Roth LJ (1953) Distribution of C14 labeled isoniazid in sensitive and resistant tubercle bacilli and in infected and uninfected tissues in tuberculous patients. Trans Annu Meet Natl Tuberc Assoc 49: 192-195.
6. Basaraba RJ (2008) Experimental tuberculosis: the role of comparative pathology in the discovery of improved tuberculosis treatment strategies. Tuberculosis (Edinb) 88(Suppl 1): S35-S47.
7. Cruz AT, Starke JR & Lobato MN (2013) Old and new approaches to diagnosing and treating latent tuberculosis in children in low-incidence countries. Curr Opin Pediatr 26: 106-113.
8. Driver ER, Ryan GJ, Hoff DR, Irwin SM, Basaraba RJ, Kramnik I & Lenaerts AJ (2012) Evaluation of a mouse model of necrotic granuloma formation using C3HeB/FeJ mice for testing of drugs against Mycobacterium tuberculosis. Antimicrob Agents Chemother 56: 3181-3195.
9. Ehlers S & Schaible UE (2012) The granuloma in tuberculosis: dynamics of a host-pathogen collusion. Front Immunol 3: 411.
10. Franzblau SG, Witzig RS, McLaughlin JC et al. (1998) Rapid, low-technology MIC determination with clinical Mycobacterium tuberculosis isolates by using the microplate Alamar Blue assay. J Clin Microbiol 36: 362-366.
11. Harris TL, Worthington RJ & Melander C(2012)Potentsmall-molecule suppression of oxacillin resistance in methicillin-resistant Staphylococcus aureus. Angew Chem Int Ed Engl 51: 11254-11257.
12. Hoff DR, Ryan GJ, Driver ER, Ssemakulu CC, De Groote MA, Basaraba RJ & Lenaerts AJ (2011) Location of intra- and extracellular M. tuberculosis populations in lungs of mice and guinea pigs during disease progression and after drug treatment. PLoS ONE 6: e17550.
13. Huigens RW, Reyes S, Reed CS, Bunders C, Rogers SA, Steinhauer AT & Melander C (2010) The chemical synthesis and antibiotic activity of a diverse library of 2-aminobenzimidazole small molecules against MRSA and multidrug-resistant A. baumannii. Bioorg Med Chem 18: 663-674.
14. Kapoor N, Pawar S, Sirakova TD, Deb C, Warren WL & Kolattukudy PE (2013) Human granuloma in vitro model, for TB dormancy and resuscitation. PLoS ONE 8: e53657.
15. Kliiman K & Altraja A (2009) Predictors of poor treatment outcome in multi- and extensively drug-resistant pulmonary TB. Eur Respir J 33: 1085-1094.
16. Lee W, VanderVen BC, Fahey RJ & Russell DG (2013) Intracellular Mycobacterium tuberculosis exploits host-derived fatty acids to limit metabolic stress. J Biol Chem 288: 6788-6800.
17. Lenaerts AJ, Hoff D, Aly S et al. (2007) Location of persisting mycobacteria in a Guinea pig model of tuberculosis revealed by r207910. Antimicrob Agents Chemother 51: 3338-3345.
18. Lindsey EA, Worthington RJ, Alcaraz C & Melander C (2012) 2-Aminopyrimidine as a novel scaffold for biofilm modulation. Org Biomol Chem 10: 2552-2561.
19. Lindsey EA, Brackett CM, Mullikin T, Alcaraz C & Melander C (2012) The discovery of N-1 substituted 2-aminobenzimidazoles as zinc-dependent S. aureus biofilm inhibitors. Medchemcomm 3: 1462-1465.
20. Manthei RW, Roth LJ, Barclay WR & Ebert RH (1954) The distribution of C14 labeled isoniazid in normal and infected guinea pigs. Arch Int Pharmacodyn Ther 98: 183-192.
21. Mitchison D & Davies G (2012) The chemotherapy of tuberculosis: past, present and future. Int J Tuberc Lung Dis 16: 724-732.
22. Ojha AK, Baughn AD, Sambandan D et al. (2008) Growth of Mycobacterium tuberculosis biofilms containing free mycolic acids and harbouring drug-tolerant bacteria. Mol Microbiol 69: 164-174.
23. Orme IM (2014) A new unifying theory of the pathogenesis of tuberculosis. Tuberculosis (Edinb) 94: 8-14.
24. Pang JM, Layre E, Sweet L, Sherrid A, Moody DB, Ojha A & Sherman DR (2012) The polyketide Pks1 contributes to biofilm formation in Mycobacterium tuberculosis. J Bacteriol 194: 715-721.
25. Prideaux B, Dartois V, Staab D et al. (2011) High-sensitivity MALDI-MRM-MS imaging of moxifloxacin distribution in tuberculosis- infected rabbit lungs and granulomatous lesions. Anal Chem 83: 2112-2118.
26. Ramsugit S, Guma S, Pillay B, Jain P, Larsen MH, Danaviah S & Pillay M (2013) Pili contribute to biofilm formation in vitro in Mycobacterium tuberculosis. Antonie Van Leeuwenhoek 104: 725-735.
27. Richards JJ, Ballard TE & Melander C (2008) Inhibition and dispersion of Pseudomonas aeruginosa biofilms with reverse amide 2-aminoimidazole oroidin analogues. Org Biomol Chem 6: 1356-1363.
28. Rogers SA & Melander C (2008) Construction and screening of a 2-aminoimidazole library identifies a small molecule capable of inhibiting and dispersing biofilms across bacterial order, class, and phylum. Angew Chem Int Ed 47: 5229-5231.
29. Rogers SA, Bero JD & Melander C (2010) Chemical synthesis and biological screening of 2-aminoimidazole-based bacterial and fungal antibiofilm agents. ChemBioChem 11: 396-410.
30. Ryan GJ, Hoff DR, Driver ER et al. (2010) Multiple M. tuberculosis phenotypes in mouse and guinea pig lung tissue revealed by a dual-staining approach. PLoS ONE 5: e11108.
31. Sambandan D, Dao DN, Weinrick BC et al. (2013) Keto-mycolic acid-dependent pellicle formation confers tolerance to drug-sensitive Mycobacterium tuberculosis. MBio 4: e00222-00213.
32. Shang S, Shanley CA, Caraway ML et al. (2012) Drug treatment combined with BCG vaccination reduces disease reactivation in guinea pigs infected with Mycobacterium tuberculosis. Vaccine 30: 1572-1582.
33. Stewart PS & Franklin MJ (2008) Physiological heterogeneity in biofilms. Nat Rev Microbiol 6: 199-210.
34. Thompson RJ, Bobay BG, Stowe SD et al. (2012) Identification of BfmR, a response regulator involved in biofilm development, as a target for a 2-Aminoimidazole-based antibiofilm agent. Biochemistry 51: 9776-9778.
35. Worthington RJ, Richards JJ & Melander C (2012a) Small molecule control of bacterial biofilms. Org Biomol Chem 10: 7457-7474.
36. Worthington RJ, Bunders CA, Reed CS & Melander C (2012b) Small molecule suppression of carbapenem resistance in NDM-1 producing Klebsiella pneumoniae. ACS Med Chem Lett 3: 357- 361.
37. Worthington RJ, Blackledge MS & Melander C (2013) Small molecule inhibition of bacterial two-component systems to combat antibiotic resistance and virulence. Future Med Chem, 5: 1265-1284